Urologix, Inc. - Earning & Dividend Analysis Snapshot

This detailed Report provides an Earnings and Dividends history for Urologix, Inc.. Tabular results include up to a ten-year history of "as reported" Earnings per Share and Dividends per Share plus a calculation of the amount of earnings paid out over the year in dividends (i.e. Payout Ratio). Earnings and Dividends are presented on both a Quarterly and Annual basis. An annual Percent Change factor is calculated for both Earnings and Dividends.

Urologix, Inc.. The Company's principal activity is to develop, manufacture and market non-surgical, catheter-based therapies for the treatment of benign prostatic hyperplasia. The Group market its control units under the CoolWave(R) and Targis(R) names and its procedure kits under the CTC AdvanceTM, CTCTM, Targis, and ProstaprobeTM names. It uses a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia disease. The Cooled ThermoTherapy can be performed without anesthesia or intravenous sedation and it can be performed in a physician's office or an outpatient clinic. The therapy provides a safe solution that is superior to medication without the complications and side effects inherent in surgical procedures. It manufacture the Targis control unit, CoolWave control unit, and single-use treatment catheters. The Company operates in the United States, Europe, Canada, Asia and other countries.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report